The novel isoflavone 7-hydroxy-3',4'-benzoisoflavone induces cell apoptosis in human osteosarcoma cells
Chun-Han Hou1, Yi-Chin Fong, Jung-Tsan Chen
1Institute of Biomedical Engineering, National Taiwan University, Taipei, Taiwan.
Abstract:
Osteosarcoma is the most frequent primitive malignant tumor of the skeletal system and is characterized by an extremely aggressive clinical course that lacks an effective treatment. This study is the first to investigate the anti-cancer effects of a new isoflavone-derived 7-hydroxy-3',4'-benzoisoflavone (HBI) in human osteosarcoma cells. HBI-induced cell apoptosis in human osteosarcoma cell lines. The accumulation of reactive oxygen species (ROS) is a critical mediator in HBI induced cell death. HBI also induced apoptosis signal-regulating kinase 1 (ASK1) dephosphorylation, p38, JNK and p53 phosphorylation. Transfection with ASK1, p38 and JNK small interfering RNA (siRNA) antagonized HBI-induced cell apoptosis. HBI also triggered the mitochondrial apoptotic pathway, as indicated by a change in Bax/Bcl2 ratio. Bax knockdown using a Bax siRNA strategy reduced Bax expression and subsequent cell death. In addition, ASK1, p38 and JNK siRNA reduced HBI-induced p53 phosphorylation and Bax expression. These results suggest that the ROS-ASK1-p38/JNK-p53 and Bax pathway plays a critical role in HBI's anti-cancer effects.
Insights
This study reveals that 7-hydroxy-3
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Osteosarcoma is a prevalent and aggressive skeletal cancer with limited treatment options.
- Investigating novel therapeutic agents is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the anti-cancer potential of 7-hydroxy-3',4'-benzoisoflavone (HBI) in human osteosarcoma cells.
- To elucidate the molecular mechanisms underlying HBI-induced cell death.
Main Methods:
- Human osteosarcoma cell lines were treated with HBI.
- Assays were performed to measure reactive oxygen species (ROS) levels, apoptosis markers, and protein phosphorylation/dephosphorylation.
- Small interfering RNA (siRNA) was used to knockdown specific genes (ASK1, p38, JNK, Bax).
Main Results:
- HBI induced significant apoptosis in osteosarcoma cells.
- HBI treatment led to increased ROS accumulation, ASK1 dephosphorylation, and phosphorylation of p38, JNK, and p53.
- Knockdown of ASK1, p38, JNK, or Bax attenuated HBI-induced apoptosis.
- HBI modulated the mitochondrial apoptotic pathway by altering the Bax/Bcl2 ratio.
Conclusions:
- The novel isoflavone derivative HBI exhibits potent anti-cancer effects against osteosarcoma.
- HBI-induced apoptosis is mediated by the ROS-ASK1-p38/JNK-p53-Bax signaling pathway.
More Related Videos
Related Concept Videos
Apoptosis
Cancer Prevention
Some...
The Intrinsic Apoptotic Pathway


